|
|
Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012. Hung Chin-Chuan, et al. [Article:22188362@PubMed] |
|
|
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics. 2012. Brown Kevin C, et al. [Article:22111602@PubMed] |
|
|
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012. Zhang Wei, et al. [Article:22248286@PubMed] |
|
|
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. The pharmacogenomics journal. 2012. Martis S, et al. [Article:22491019@PubMed] |
|
|
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals. Therapeutic drug monitoring. 2012. Heil Sandra G, et al. [Article:22354160@PubMed] |
|
|
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic & clinical pharmacology & toxicology. 2011. Gozalo Claire, et al. [Article:21824325@PubMed] |
|
|
Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices. British journal of clinical pharmacology. 2011. Calcagno A, et al. [Article:22188122@PubMed] |
|
|
Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chinese medical journal. 2011. Zhang Bai-Lin, et al. [Article:21362365@PubMed] |
|
|
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. [Article:21502584@PubMed] |
|
|
ABCB1 Single-Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis. Clinical pharmacology and therapeutics. 2011. Herrlinger K R, et al. [Article:21289623@PubMed] |
|
|
Drug Interactions Between the Immunosuppressant Tacrolimus and the Cholesterol Absorption Inhibitor Ezetimibe in Healthy Volunteers. Clinical pharmacology and therapeutics. 2011. Oswald S, et al. [Article:21368751@PubMed] |
|
|
Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions. Clinical pharmacology and therapeutics. 2011. Kacevska M, et al. [Article:21508940@PubMed] |
|
|
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. [Article:21289622@PubMed] |
|
|
In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011. Zhang Chunbo, et al. [Article:21692796@PubMed] |
|
|
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Visscher Henk, et al. [Article:21900104@PubMed] |
|
|
Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. Journal of clinical pharmacology. 2011. Zwisler Stine T, et al. [Article:21383334@PubMed] |
|
|
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leukemia research. 2011. Cibeira MarÃa Teresa, et al. [Article:21435719@PubMed] |
|
|
ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenetics and genomics. 2011. Lin Keh-Ming, et al. [Article:20859246@PubMed] |
|
|
PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenetics and genomics. 2011. Sangkuhl Katrin, et al. [Article:21546862@PubMed] |
|
|
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. [Article:20216335@PubMed] |
|
|
ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. Pharmacogenomics. 2011. L'Huillier Arnaud G, et al. [Article:21902503@PubMed] |
|
|
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011. Giovannetti Elisa, et al. [Article:22026922@PubMed] |
|
|
Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics. 2011. Haerian Batoul Sadat, et al. [Article:21391884@PubMed] |
|
|
Central neurotoxicity in cancer chemotherapy: pharmacogenetic insights. Pharmacogenomics. 2011. Froklage Femke Eam, et al. [Article:21449677@PubMed] |
|
|
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011. Perroud Nader, et al. [Article:21449676@PubMed] |
|
|
Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics. 2011. Dandara Collet, et al. [Article:22118051@PubMed] |
|
|
Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics. 2011. Narumiya Kosuke, et al. [Article:21332314@PubMed] |
|
|
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011. Hung Chin-Chuan, et al. [Article:21902500@PubMed] |
|
|
Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics. 2011. Rideg Orsolya, et al. [Article:21806387@PubMed] |
|
|
Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics. 2011. Risselada Arne J, et al. [Article:21843067@PubMed] |
|
|
Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 2011. Santoro Ana, et al. [Article:21806386@PubMed] |
|
|
The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011. de Jonge Hylke, et al. [Article:21770725@PubMed] |
|
|
Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011. Müller Fabian, et al. [Article:21787191@PubMed] |
|
|
C3435T polymorphism of the ABCB1 gene: impact on genetic susceptibility to peptic ulcers. Pharmacological reports : PR. 2011. Sa¿agacka Aleksandra, et al. [Article:22001987@PubMed] |
|
|
Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological reports : PR. 2011. Baer-Dubowska Wanda, et al. [Article:21602587@PubMed] |
|
|
An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics. The pharmacogenomics journal. 2011. Wolf S J, et al. [Article:21625253@PubMed] |
|
|
Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. The pharmacogenomics journal. 2011. Kuzman M R, et al. [Article:20195292@PubMed] |
|
|
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. The pharmacogenomics journal. 2011. Yimer G, et al. [Article:21862974@PubMed] |
|
|
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. The pharmacogenomics journal. 2011. Scott S A, et al. [Article:21358751@PubMed] |
|
|
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The pharmacogenomics journal. 2011. Glimelius B, et al. [Article:20177420@PubMed] |
|
|
Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011. Jacobson Pamala A, et al. [Article:21206424@PubMed] |
|
|
MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission. AIDS (London, England). 2010. Bellusci Carolina P, et al. [Article:20124970@PubMed] |
|
|
Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. American journal of obstetrics and gynecology. 2010. Hemauer Sarah J, et al. [Article:20350646@PubMed] |
|
|
Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia. 2010. Choi E M, et al. [Article:20707787@PubMed] |
|
|
Population Pharmacokinetic modelling of the association between 63396C->T Pregnane-X-Receptor (PXR) polymorphism and unboosted atazanavir clearance. Antimicrobial agents and chemotherapy. 2010. Schipani Alessandro, et al. [Article:20921307@PubMed] |
|
|
Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie. 2010. Grover Sandeep, et al. [Article:20417680@PubMed] |
|
|
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer. 2010. Bray J, et al. [Article:20179710@PubMed] |
|
|
Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. British journal of pharmacology. 2010. Yang Tao, et al. [Article:20977453@PubMed] |
|
|
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer chemotherapy and pharmacology. 2010. Harmsen Stefan, et al. [Article:20041327@PubMed] |
|
|
Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer epidemiology. 2010. HenrÃquez-Hernández Luis Alberto, et al. [Article:20638924@PubMed] |
|
|
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clinical pharmacokinetics. 2010. Staatz Christine E, et al. [Article:20170205@PubMed] |
|
|
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clinical pharmacokinetics. 2010. Staatz Christine E, et al. [Article:20214406@PubMed] |
|
|
A Phenotype-Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clinical pharmacology and therapeutics. 2010. Dumond J B, et al. [Article:20147896@PubMed] |
|
|
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. [Article:20981002@PubMed] |
|
|
Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clinical pharmacology and therapeutics. 2010. Woillard J-B, et al. [Article:20505666@PubMed] |
|
|
Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?. Clinical pharmacology and therapeutics. 2010. van Gelder T, et al. [Article:20485320@PubMed] |
|
|
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Oswald S, et al. [Article:20220747@PubMed] |
|
|
Prediction of adverse drug reactions using decision tree modeling. Clinical pharmacology and therapeutics. 2010. Hammann F, et al. [Article:20220749@PubMed] |
|
|
The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin. Clinical pharmacology and therapeutics. 2010. Burk O, et al. [Article:20844484@PubMed] |
|
|
Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M. [Article:19890253@PubMed] |
|
|
The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundamental & clinical pharmacology. 2010. Zwisler Stine T, et al. [Article:19845769@PubMed] |
|
|
Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. International journal of hygiene and environmental health. 2010. Chen Songjian, et al. [Article:20189873@PubMed] |
|
|
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010. Wallentin Lars, et al. [Article:20801498@PubMed] |
|
|
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010. Mega Jessica L, et al. [Article:20801494@PubMed] |
|
|
Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leukemia research. 2010. Hartman A, et al. [Article:19467705@PubMed] |
|
|
MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Medical oncology (Northwood, London, England). 2010. Paule Bernard, et al. [Article:19862647@PubMed] |
|
|
ABC transporters in cancer: more than just drug efflux pumps. Nature reviews. Cancer. 2010. Fletcher Jamie I, et al. [Article:20075923@PubMed] |
|
|
Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. Pediatric nephrology (Berlin, Germany). 2010. Leroy Sandrine, et al. [Article:20091056@PubMed] |
|
|
Clopidogrel pathway. Pharmacogenetics and genomics. 2010. Sangkuhl Katrin, et al. [Article:20440227@PubMed] |
|
|
Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:21048526@PubMed] |
|
|
Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics and genomics. 2010. Stamp Lisa K, et al. [Article:20386493@PubMed] |
|
|
ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics. 2010. Gonzalez-Haba Eva, et al. [Article:21142915@PubMed] |
|
|
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010. Capron Arnaud, et al. [Article:20415563@PubMed] |
|
|
Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach. Pharmacogenomics. 2010. Pallet Nicolas, et al. [Article:21047207@PubMed] |
|
|
Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics. 2010. Errasti-Murugarren Ekaitz, et al. [Article:20504255@PubMed] |
|
|
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics. 2010. Kooloos Wouter M, et al. [Article:20136356@PubMed] |
|
|
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al. [Article:20602612@PubMed] |
|
|
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010. Elens Laure, et al. [Article:20860463@PubMed] |
|
|
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010. Ciccacci Cinzia, et al. [Article:20017669@PubMed] |
|
|
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics. 2010. Peters Bas J M, et al. [Article:20712525@PubMed] |
|
|
Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010. Yee Sook Wah, et al. [Article:20350125@PubMed] |
|
|
SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010. Michelon Hugues, et al. [Article:21142914@PubMed] |
|
|
Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics. 2010. Potschka Heidrun. [Article:21047204@PubMed] |
|
|
Update on the clinical pharmacogenomics of organ transplantation. Pharmacogenomics. 2010. Burckart Gilbert J, et al. [Article:20136361@PubMed] |
|
|
Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics. 2010. Wang Ping, et al. [Article:21047202@PubMed] |
|
|
Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. Pharmacogenomics. 2010. Gassó Patricia, et al. [Article:21142916@PubMed] |
|
|
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. The Annals of pharmacotherapy. 2010. Smith Nicola F, et al. [Article:20959500@PubMed] |
|
|
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. The Journal of infectious diseases. 2010. Ribaudo Heather J, et al. [Article:20662624@PubMed] |
|
|
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. The pharmacogenomics journal. 2010. Gréen H, et al. [Article:20938465@PubMed] |
|
|
Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. The pharmacogenomics journal. 2010. Mas S, et al. [Article:21173786@PubMed] |
|
|
MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. The pharmacogenomics journal. 2010. Cizmarikova M, et al. [Article:19752884@PubMed] |
|
|
Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. The pharmacogenomics journal. 2010. Correia C T, et al. [Article:19997080@PubMed] |
|
|
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. The pharmacogenomics journal. 2010. Leskelä S, et al. [Article:20212519@PubMed] |
|
|
The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. The pharmacogenomics journal. 2010. Reed K, et al. [Article:20125118@PubMed] |
|
|
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. The pharmacogenomics journal. 2010. Cecchin E, et al. [Article:20368715@PubMed] |
|
|
Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Therapeutic drug monitoring. 2010. Kuypers Dirk R J, et al. [Article:20526235@PubMed] |
|
|
Use of pharmacogenetics to optimize immunosuppressive therapy. Therapeutic drug monitoring. 2010. Macphee Iain A M. [Article:20431509@PubMed] |
|
|
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association. 2010. Goldberg Richard M, et al. [Article:20697547@PubMed] |
|
|
CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation. 2010. Min Sang-Il, et al. [Article:21076384@PubMed] |
|
|
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009. Chang H, et al. [Article:18836089@PubMed] |
|
|
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic & clinical pharmacology & toxicology. 2009. Gréen Henrik, et al. [Article:19143748@PubMed] |
|
|
ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochemical pharmacology. 2009. Rebecchi Ivanise Marina Moretti, et al. [Article:18851956@PubMed] |
|
|
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer chemotherapy and pharmacology. 2009. Fujita Ken-Ichi, et al. [Article:19466410@PubMed] |
|
|
MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer chemotherapy and pharmacology. 2009. Woodahl Erica L, et al. [Article:19123050@PubMed] |
|
|
Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clinica chimica acta; international journal of clinical chemistry. 2009. Jeannesson Elise, et al. [Article:19285054@PubMed] |
|
|
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al. [Article:19458058@PubMed] |
|
|
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009. RodrÃguez-Nóvoa Sonia, et al. [Article:19400747@PubMed] |
|
|
Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clinical pharmacology and therapeutics. 2009. Fenner K S, et al. [Article:18987624@PubMed] |
|
|
Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clinical pharmacology and therapeutics. 2009. Birkenfeld A L, et al. [Article:19776737@PubMed] |
|
|
Macrolide-induced digoxin toxicity: a population-based study. Clinical pharmacology and therapeutics. 2009. Gomes T, et al. [Article:19606089@PubMed] |
|
|
Pharmacoepigenetics: its role in interindividual differences in drug response. Clinical pharmacology and therapeutics. 2009. Gomez A, et al. [Article:19242404@PubMed] |
|
|
Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clinical pharmacology and therapeutics. 2009. Zhao W, et al. [Article:19865079@PubMed] |
|
|
The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. Clinical pharmacology and therapeutics. 2009. Mahungu T W, et al. [Article:19474786@PubMed] |
|
|
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug metabolism and disposition: the biological fate of chemicals. 2009. Tolson Antonia H, et al. [Article:19520773@PubMed] |
|
|
Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert opinion on drug metabolism & toxicology. 2009. Phan Viet Hong, et al. [Article:19331590@PubMed] |
|
|
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecologic oncology. 2009. Kim Hee Seung, et al. [Article:19203783@PubMed] |
|
|
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV medicine. 2009. Mahungu Tw, et al. [Article:19228205@PubMed] |
|
|
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational new drugs. 2009. Oostendorp Roos L, et al. [Article:18449471@PubMed] |
|
|
CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. Journal of clinical pharmacology. 2009. Hennessy Sean, et al. [Article:19617466@PubMed] |
|
|
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. Journal of clinical psychopharmacology. 2009. Jaquenoud Sirot Eveline, et al. [Article:19593168@PubMed] |
|
|
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. Journal of human genetics. 2009. Cha Pei-Chieng, et al. [Article:19696792@PubMed] |
|
|
Pharmacogenetics in cardiovascular antithrombotic therapy. Journal of the American College of Cardiology. 2009. MarÃn Francisco, et al. [Article:19744613@PubMed] |
|
|
Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. Journal of the American Society of Nephrology : JASN. 2009. Naesens Maarten, et al. [Article:19762492@PubMed] |
|
|
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2009. Rocha V, et al. [Article:19005482@PubMed] |
|
|
Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Molecular biology reports. 2009. Turgut Gunfer, et al. [Article:18165917@PubMed] |
|
|
Codeine and morphine pathway. Pharmacogenetics and genomics. 2009. Thorn Caroline F, et al. [Article:19512957@PubMed] |
|
|
Taxane Pathway. Pharmacogenetics and genomics. 2009. Oshiro Connie, et al. [Article:21151855@PubMed] |
|
|
ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics. 2009. Estrela Rita de Cassia, et al. [Article:19207033@PubMed] |
|
|
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics. 2009. Consoli Giorgio, et al. [Article:19663671@PubMed] |
|
|
CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics. 2009. Bochud Murielle, et al. [Article:19290795@PubMed] |
|
|
Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics. 2009. Becker Matthijs L, et al. [Article:19891551@PubMed] |
|
|
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics. 2009. Ufer Mike, et al. [Article:19958093@PubMed] |
|
|
Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics. 2009. Kwan Patrick, et al. [Article:19450124@PubMed] |
|
|
Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics. 2009. Oliveira Elisabete, et al. [Article:19761365@PubMed] |
|
|
Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics. 2009. Roumier Christophe, et al. [Article:19891558@PubMed] |
|
|
Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacological reports : PR. 2009. He Xiao-Jing, et al. [Article:19904007@PubMed] |
|
|
Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PloS one. 2009. Hesselson Stephanie E, et al. [Article:19742321@PubMed] |
|
|
Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford, England). 2009. Lee Yvonne C, et al. [Article:19193698@PubMed] |
|
|
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (New York, N.Y.). 2009. Aller Stephen G, et al. [Article:19325113@PubMed] |
|
|
Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. The Laryngoscope. 2009. Grau Juan J, et al. [Article:19504558@PubMed] |
|
|
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. [Article:19106083@PubMed] |
|
|
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. The pharmacogenomics journal. 2009. Guo J, et al. [Article:19188929@PubMed] |
|
|
Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. The pharmacogenomics journal. 2009. McBride B F, et al. [Article:19204737@PubMed] |
|
|
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Therapeutic drug monitoring. 2009. Press Rogier R, et al. [Article:19258929@PubMed] |
|
|
Pharmacogenetics of morphine: Potential implications in sickle cell disease. American journal of hematology. 2008. Darbari Deepika S, et al. [Article:17722074@PubMed] |
|
|
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC cancer. 2008. Huang Ming-Yii, et al. [Article:18267032@PubMed] |
|
|
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008. Dulucq Stéphanie, et al. [Article:18524988@PubMed] |
|
|
ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. British journal of clinical pharmacology. 2008. Zhang Ya-tong, et al. [Article:18717915@PubMed] |
|
|
Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer science. 2008. Lal Suman, et al. [Article:18377430@PubMed] |
|
|
An overview of cancer multidrug resistance: a still unsolved problem. Cellular and molecular life sciences : CMLS. 2008. Lage H. [Article:18581055@PubMed] |
|
|
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clinical pharmacology and therapeutics. 2008. Keskitalo J E, et al. [Article:19238649@PubMed] |
|
|
Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clinical pharmacology and therapeutics. 2008. Campa D, et al. [Article:17898703@PubMed] |
|
|
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clinical pharmacology and therapeutics. 2008. Hebert M F, et al. [Article:18288078@PubMed] |
|
|
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical pharmacology and therapeutics. 2008. Wang L, et al. [Article:17568400@PubMed] |
|
|
Genetic variation in drug transporters in ethnic populations. Clinical pharmacology and therapeutics. 2008. Cropp C D, et al. [Article:18528433@PubMed] |
|
|
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clinical pharmacology and therapeutics. 2008. Ufer M, et al. [Article:18322448@PubMed] |
|
|
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clinical pharmacology and therapeutics. 2008. Magnusson M O, et al. [Article:17971810@PubMed] |
|
|
Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug metabolism and disposition: the biological fate of chemicals. 2008. Yeung Eugene Y H, et al. [Article:18725505@PubMed] |
|
|
Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug metabolism and disposition: the biological fate of chemicals. 2008. Morimoto Kaori, et al. [Article:17940134@PubMed] |
|
|
A genomic "roadmap" to "better" drugs. Drug metabolism reviews. 2008. Liao Guochun, et al. [Article:18464044@PubMed] |
|
|
Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. European journal of clinical pharmacology. 2008. Bohanec Grabar Petra, et al. [Article:18607581@PubMed] |
|
|
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Human molecular genetics. 2008. Levran Orna, et al. [Article:18424454@PubMed] |
|
|
Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. International journal of cancer. Journal international du cancer. 2008. Nordgard Silje H, et al. [Article:18498133@PubMed] |
|
|
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of psychiatric research. 2008. Alenius Malin, et al. [Article:18086475@PubMed] |
|
|
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. [Article:18215618@PubMed] |
|
|
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenetics and genomics. 2008. Aarnoudse Albert-Jan L H J, et al. [Article:18334914@PubMed] |
|
|
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenetics and genomics. 2008. Hindorff Lucia A, et al. [Article:18622260@PubMed] |
|
|
Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenetics and genomics. 2008. Kuypers Dirk R, et al. [Article:18704002@PubMed] |
|
|
Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenetics and genomics. 2008. Hung Chin-Chuan, et al. [Article:18408562@PubMed] |
|
|
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenetics and genomics. 2008. Fukudo Masahide, et al. [Article:18408564@PubMed] |
|
|
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenetics and genomics. 2008. Crettol Séverine, et al. [Article:18334915@PubMed] |
|
|
Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenetics and genomics. 2008. Sharma Shruti, et al. [Article:19093297@PubMed] |
|
|
MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenetics and genomics. 2008. Maggini Valentina, et al. [Article:18408561@PubMed] |
|
|
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenetics and genomics. 2008. Fanta Samuel, et al. [Article:18192894@PubMed] |
|
|
Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenetics and genomics. 2008. Vaclavikova Radka, et al. [Article:18300948@PubMed] |
|
|
Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008. Madadi Parvaz, et al. [Article:18781855@PubMed] |
|
|
Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics. 2008. Rollason Victoria, et al. [Article:18597654@PubMed] |
|
|
Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics. 2008. Kronenberg Sefi, et al. [Article:19018726@PubMed] |
|
|
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. Nikisch Georg, et al. [Article:18940259@PubMed] |
|
|
Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology. 2008. Xu Ping, et al. [Article:18810246@PubMed] |
|
|
A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. The Journal of pharmacology and experimental therapeutics. 2008. Yang Ziping, et al. [Article:18723777@PubMed] |
|
|
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. The Journal of rheumatology. 2008. Ranganathan Prabha, et al. [Article:18381794@PubMed] |
|
|
ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136. The pharmacogenomics journal. 2008. Aird R E, et al. [Article:17563765@PubMed] |
|
|
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. The pharmacogenomics journal. 2008. Erdilyi D J, et al. [Article:17938643@PubMed] |
|
|
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. [Article:18668431@PubMed] |
|
|
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al. [Article:18668430@PubMed] |
|
|
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007. Kishi Shinji, et al. [Article:17264302@PubMed] |
|
|
Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. British journal of clinical pharmacology. 2007. Kim Kyoung-Ah, et al. [Article:16869811@PubMed] |
|
|
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007. Mensah-Osman Edith J, et al. [Article:17279585@PubMed] |
|
|
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer biology & therapy. 2007. Li Jing, et al. [Article:17312388@PubMed] |
|
|
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clinical pharmacology and therapeutics. 2007. Kuypers D R J, et al. [Article:17495880@PubMed] |
|
|
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clinical pharmacology and therapeutics. 2007. Renders L, et al. [Article:17192769@PubMed] |
|
|
Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clinical pharmacology and therapeutics. 2007. Frassetto L A, et al. [Article:17361125@PubMed] |
|
|
Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clinical pharmacology and therapeutics. 2007. Park H-J, et al. [Article:17192767@PubMed] |
|
|
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clinical pharmacology and therapeutics. 2007. Gurney H, et al. [Article:17495881@PubMed] |
|
|
Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clinical pharmacology and therapeutics. 2007. Schwarz U I, et al. [Article:17392718@PubMed] |
|
|
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clinical pharmacology and therapeutics. 2007. Glaeser H, et al. [Article:17215845@PubMed] |
|
|
Pharmacogenetics of opioids. Clinical pharmacology and therapeutics. 2007. Somogyi Andrew A, et al. [Article:17339873@PubMed] |
|
|
The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clinical pharmacology and therapeutics. 2007. la Porte C J L, et al. [Article:17361121@PubMed] |
|
|
Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy & behavior : E&B. 2007. Kwan Patrick, et al. [Article:17521963@PubMed] |
|
|
The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy research. 2007. Shahwan Amre, et al. [Article:17125969@PubMed] |
|
|
Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. European journal of clinical pharmacology. 2007. Comets Emmanuelle, et al. [Article:17404720@PubMed] |
|
|
MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflammatory bowel diseases. 2007. Mendoza Juan L, et al. [Article:17262810@PubMed] |
|
|
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflammatory bowel diseases. 2007. Daniel Fady, et al. [Article:17206635@PubMed] |
|
|
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Marsh Sharon, et al. [Article:17925548@PubMed] |
|
|
Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. Molecular nutrition & food research. 2007. Moon Young Jin, et al. [Article:17340576@PubMed] |
|
|
MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatric nephrology (Berlin, Germany). 2007. Wasilewska Anna, et al. [Article:17043887@PubMed] |
|
|
1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenetics and genomics. 2007. Elens Laure, et al. [Article:17885626@PubMed] |
|
|
ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. Pharmacogenetics and genomics. 2007. Sam Soya Sisy, et al. [Article:17885624@PubMed] |
|
|
Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics. 2007. Hung Chin-Chuan, et al. [Article:17924830@PubMed] |
|
|
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007. Ma Qing, et al. [Article:17324111@PubMed] |
|
|
Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacological reports : PR. 2007. Bartnicka Lilianna, et al. [Article:17652833@PubMed] |
|
|
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (New York, N.Y.). 2007. Kimchi-Sarfaty Chava, et al. [Article:17185560@PubMed] |
|
|
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. The pharmacogenomics journal. 2007. Leschziner G D, et al. [Article:16969364@PubMed] |
|
|
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. The pharmacogenomics journal. 2007. Haenisch S, et al. [Article:16788565@PubMed] |
|
|
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. The pharmacogenomics journal. 2007. Marsh S, et al. [Article:17224914@PubMed] |
|
|
Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Therapeutic drug monitoring. 2007. Ebid Abdel-Hameed I Mohammed, et al. [Article:17529887@PubMed] |
|
|
[Association of a polymorphism in MDR1 C3435T with response to antiepileptic drug treatment in ethic Han Chinese children with epilepsy]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2007. Chen Li, et al. [Article:17306068@PubMed] |
|
|
The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 2006. Stamp Lisa, et al. [Article:17071051@PubMed] |
|
|
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al. [Article:16651435@PubMed] |
|
|
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Lagas Jurjen S, et al. [Article:17062689@PubMed] |
|
|
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Gréen Henrik, et al. [Article:16467099@PubMed] |
|
|
ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clinical chemistry. 2006. Laika Barbara, et al. [Article:16638956@PubMed] |
|
|
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Ritchie Marylyn D, et al. [Article:16912956@PubMed] |
|
|
Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Lee Lawrence S, et al. [Article:16983620@PubMed] |
|
|
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Haas David W, et al. [Article:16912957@PubMed] |
|
|
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clinical pharmacology and therapeutics. 2006. Crettol Séverine, et al. [Article:17178267@PubMed] |
|
|
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clinical pharmacology and therapeutics. 2006. van der Holt Bronno, et al. [Article:17112800@PubMed] |
|
|
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical pharmacology and therapeutics. 2006. Coller Janet K, et al. [Article:17178268@PubMed] |
|
|
Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clinical pharmacology and therapeutics. 2006. Oswald Stefan, et al. [Article:17112804@PubMed] |
|
|
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics. 2006. Neuvonen Pertti J, et al. [Article:17178259@PubMed] |
|
|
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. [Article:17112805@PubMed] |
|
|
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clinical pharmacology and therapeutics. 2006. Masuda Satohiro, et al. [Article:16413244@PubMed] |
|
|
MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. Clinical pharmacology and therapeutics. 2006. Meisel Peter, et al. [Article:16413242@PubMed] |
|
|
MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clinical pharmacology and therapeutics. 2006. Aarnoudse Albert L H J, et al. [Article:17015054@PubMed] |
|
|
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clinical pharmacology and therapeutics. 2006. Lamba Jatinder, et al. [Article:16580901@PubMed] |
|
|
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clinical pharmacology and therapeutics. 2006. Fukudo Masahide, et al. [Article:17015051@PubMed] |
|
|
The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug metabolism and drug interactions. 2006. Ejsing Thomas Broeng, et al. [Article:16841511@PubMed] |
|
|
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. European journal of cancer (Oxford, England : 1990). 2006. Sissung Tristan M, et al. [Article:16950614@PubMed] |
|
|
Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. International journal of cancer. Journal international du cancer. 2006. Kim Dong Hwan, et al. [Article:16331627@PubMed] |
|
|
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. International journal of clinical pharmacology and therapeutics. 2006. Miura M, et al. [Article:17190370@PubMed] |
|
|
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute. 2006. Cusatis George, et al. [Article:17148776@PubMed] |
|
|
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006. Pillot Giancarlo A, et al. [Article:17409981@PubMed] |
|
|
ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006. Seo Takayuki, et al. [Article:16753003@PubMed] |
|
|
Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics. 2006. GarcÃa-MartÃn Elena, et al. [Article:16753005@PubMed] |
|
|
Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics. 2006. Cheung Chi Yuen, et al. [Article:16753004@PubMed] |
|
|
Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics. 2006. Xing Qinghe, et al. [Article:17054409@PubMed] |
|
|
Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure : the journal of the British Epilepsy Association. 2006. Kim Dong Wook, et al. [Article:16542858@PubMed] |
|
|
Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure : the journal of the British Epilepsy Association. 2006. Kim Young Ok, et al. [Article:16386926@PubMed] |
|
|
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. The Journal of infectious diseases. 2006. Izzedine Hassane, et al. [Article:17083032@PubMed] |
|
|
Expression of drug pathway proteins is independent of tumour type. The Journal of pathology. 2006. Zhang W, et al. [Article:16508919@PubMed] |
|
|
Overview of the pharmacogenetics of HIV therapy. The pharmacogenomics journal. 2006. RodrÃguez-Nóvoa S, et al. [Article:16462814@PubMed] |
|
|
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Therapeutic drug monitoring. 2006. Lin Ying-Chi, et al. [Article:17038883@PubMed] |
|
|
Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2005. Anglicheau Dany, et al. [Article:15707415@PubMed] |
|
|
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005. Rocha Jose Claudio C, et al. [Article:15713801@PubMed] |
|
|
Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. British journal of clinical pharmacology. 2005. Chowbay Balram, et al. [Article:16042669@PubMed] |
|
|
Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer chemotherapy and pharmacology. 2005. Jin Jing, et al. [Article:15378274@PubMed] |
|
|
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Henningsson Anja, et al. [Article:16299241@PubMed] |
|
|
Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Qadir Misbah, et al. [Article:15788683@PubMed] |
|
|
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clinical pharmacokinetics. 2005. Rochat Bertrand. [Article:15828850@PubMed] |
|
|
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clinical pharmacology and therapeutics. 2005. Babaoglu Melih O, et al. [Article:16338277@PubMed] |
|
|
Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clinical pharmacology and therapeutics. 2005. Nakagami Taku, et al. [Article:16003291@PubMed] |
|
|
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clinical pharmacology and therapeutics. 2005. Fiegenbaum Marilu, et al. [Article:16321621@PubMed] |
|
|
Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia. 2005. Sills Graeme J, et al. [Article:15857428@PubMed] |
|
|
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. [Article:16239245@PubMed] |
|
|
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International journal of cancer. Journal international du cancer. 2005. Huisman Maarten T, et al. [Article:15849751@PubMed] |
|
|
Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. Journal of clinical pharmacology. 2005. Putnam Wendy S, et al. [Article:15778422@PubMed] |
|
|
Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. Journal of clinical pharmacology. 2005. Zheng Hongxia, et al. [Article:15778421@PubMed] |
|
|
The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Molecular endocrinology (Baltimore, Md.). 2005. Masuyama Hisashi, et al. [Article:15650019@PubMed] |
|
|
Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Molecular pharmacology. 2005. Burk Oliver, et al. [Article:15761118@PubMed] |
|
|
CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenetics and genomics. 2005. Allabi Aurel C, et al. [Article:16220110@PubMed] |
|
|
Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics. 2005. Hung Chin-Chuan, et al. [Article:16004559@PubMed] |
|
|
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proceedings of the National Academy of Sciences of the United States of America. 2005. Tate Sarah K, et al. [Article:15805193@PubMed] |
|
|
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. The Journal of clinical investigation. 2005. Kager Leo, et al. [Article:15630450@PubMed] |
|
|
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. The Journal of infectious diseases. 2005. Haas David W, et al. [Article:16267764@PubMed] |
|
|
An association study of 43 SNPs in 16 candidate genes with atorvastatin response. The pharmacogenomics journal. 2005. Thompson J F, et al. [Article:16103896@PubMed] |
|
|
Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrobial agents and chemotherapy. 2004. Sugie Masami, et al. [Article:14982769@PubMed] |
|
|
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004. Kishi Shinji, et al. [Article:12969965@PubMed] |
|
|
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. British journal of clinical pharmacology. 2004. Mai Ingrid, et al. [Article:15521904@PubMed] |
|
|
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical pharmacology and therapeutics. 2004. Marzolini Catia, et al. [Article:14749689@PubMed] |
|
|
Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Current topics in medicinal chemistry. 2004. Sakaeda Toshiyuki, et al. [Article:15379652@PubMed] |
|
|
Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. Drug metabolism and disposition: the biological fate of chemicals. 2004. Mitin Tim, et al. [Article:15258100@PubMed] |
|
|
Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene therapy. 2004. Yagüe E, et al. [Article:15164094@PubMed] |
|
|
Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome research. 2004. Soranzo Nicole, et al. [Article:15197162@PubMed] |
|
|
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. Journal of clinical pharmacology. 2004. Zheng HongXia, et al. [Article:14747421@PubMed] |
|
|
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004. Illmer T, et al. [Article:14724652@PubMed] |
|
|
Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology. 2004. Tan N C K, et al. [Article:15452306@PubMed] |
|
|
Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharmaceutical research. 2004. Pauli-Magnus Christiane, et al. [Article:15212152@PubMed] |
|
|
Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics. 2004. Ruaño Gualberto, et al. [Article:15212588@PubMed] |
|
|
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. The pharmacogenomics journal. 2004. Wadelius M, et al. [Article:14676821@PubMed] |
|
|
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. British journal of cancer. 2003. Bergman A M, et al. [Article:12799644@PubMed] |
|
|
Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chinese medical journal. 2003. Wei Hulai, et al. [Article:14642128@PubMed] |
|
|
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. Mathijssen Ron H J, et al. [Article:12960109@PubMed] |
|
|
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical pharmacology and therapeutics. 2003. Hesselink Dennis A, et al. [Article:12966368@PubMed] |
|
|
No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clinical pharmacology and therapeutics. 2003. Pauli-Magnus Christiane, et al. [Article:14586389@PubMed] |
|
|
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical pharmacology and therapeutics. 2003. Csajka Chantal, et al. [Article:12545140@PubMed] |
|
|
Digoxin pharmacokinetics and MDR1 genetic polymorphisms. European journal of clinical pharmacology. 2003. Verstuyft Céline, et al. [Article:12698307@PubMed] |
|
|
No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. European journal of medical research. 2003. Winzer Ralf, et al. [Article:14711599@PubMed] |
|
|
MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundamental & clinical pharmacology. 2003. Oselin Kersti, et al. [Article:12914549@PubMed] |
|
|
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. International journal of oncology. 2003. Kafka Ariane, et al. [Article:12684679@PubMed] |
|
|
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. Journal of acquired immune deficiency syndromes (1999). 2003. Haas David W, et al. [Article:14600574@PubMed] |
|
|
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Molecular cancer therapeutics. 2003. Brooks Tracy A, et al. [Article:14617793@PubMed] |
|
|
Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nature reviews. Cancer. 2003. Ulrich Cornelia M, et al. [Article:14740638@PubMed] |
|
|
Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharmaceutical research. 2003. Arimori Kazuhiko, et al. [Article:12817897@PubMed] |
|
|
Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharmaceutical research. 2003. Woo Jong Soo, et al. [Article:12608532@PubMed] |
|
|
MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharmaceutical research. 2003. Morita Yoshinori, et al. [Article:12739761@PubMed] |
|
|
ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics. 2003. Asano Takeshi, et al. [Article:14583680@PubMed] |
|
|
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003. Sai Kimie, et al. [Article:14646693@PubMed] |
|
|
Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. 2003. Dro¿dzik Marek, et al. [Article:12724617@PubMed] |
|
|
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003. Kroetz Deanna L, et al. [Article:12893986@PubMed] |
|
|
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proceedings of the National Academy of Sciences of the United States of America. 2003. Leabman Maya K, et al. [Article:12719533@PubMed] |
|
|
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. The New England journal of medicine. 2003. Siddiqui Asra, et al. [Article:12686700@PubMed] |
|
|
Membrane transport of folates. Vitamins and hormones. 2003. Matherly Larry H, et al. [Article:12852262@PubMed] |
|
|
The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Advanced drug delivery reviews. 2002. Fromm Martin F. [Article:12406646@PubMed] |
|
|
Interaction of common azole antifungals with P glycoprotein. Antimicrobial agents and chemotherapy. 2002. Wang Er-jia, et al. [Article:11751127@PubMed] |
|
|
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. British journal of clinical pharmacology. 2002. Drescher Siegfried, et al. [Article:11994059@PubMed] |
|
|
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. British journal of clinical pharmacology. 2002. Gerloff Thomas, et al. [Article:12492608@PubMed] |
|
|
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clinical pharmacology and therapeutics. 2002. Nakamura Tsutomu, et al. [Article:11956513@PubMed] |
|
|
Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clinical pharmacology and therapeutics. 2002. Kurata Yasuo, et al. [Article:12189368@PubMed] |
|
|
The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Human immunology. 2002. Zheng HongXia, et al. [Article:12175731@PubMed] |
|
|
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. International journal of cancer. Journal international du cancer. 2002. Stein Ulrike, et al. [Article:11857350@PubMed] |
|
|
Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. International journal of oncology. 2002. Nagata Junko, et al. [Article:12370750@PubMed] |
|
|
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002. Fellay Jacques, et al. [Article:11809184@PubMed] |
|
|
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Molecular pharmacology. 2002. Kimchi-Sarfaty Chava, et al. [Article:12065748@PubMed] |
|
|
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. [Article:12181440@PubMed] |
|
|
C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics. 2002. Goto Maki, et al. [Article:12172213@PubMed] |
|
|
Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002. Tang Kun, et al. [Article:12172212@PubMed] |
|
|
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. The Journal of clinical investigation. 2002. Fellner Stephan, et al. [Article:12417570@PubMed] |
|
|
A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. The pharmacogenomics journal. 2002. Roberts R L, et al. [Article:12082591@PubMed] |
|
|
Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology. 2002. Fromm Martin F. [Article:12505329@PubMed] |
|
|
Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002. Macphee Iain A M, et al. [Article:12490779@PubMed] |
|
|
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clinical pharmacology and therapeutics. 2001. Kim R B, et al. [Article:11503014@PubMed] |
|
|
Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Current medicinal chemistry. 2001. Dantzig A H, et al. [Article:11172691@PubMed] |
|
|
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature medicine. 2001. Synold T W, et al. [Article:11329060@PubMed] |
|
|
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's archives of pharmacology. 2001. Pauli-Magnus C, et al. [Article:11770010@PubMed] |
|
|
Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene. 2001. Turton N J, et al. [Article:11313874@PubMed] |
|
|
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001. Hitzl M, et al. [Article:11434506@PubMed] |
|
|
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. The Journal of biological chemistry. 2001. Geick A, et al. [Article:11297522@PubMed] |
|
|
Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer research. 2000. Allen J D, et al. [Article:11059771@PubMed] |
|
|
A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute. 2000. Borst P, et al. [Article:10944550@PubMed] |
|
|
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2000. Uhr M, et al. [Article:10700657@PubMed] |
|
|
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2000. Hoffmeyer S, et al. [Article:10716719@PubMed] |
|
|
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proceedings of the National Academy of Sciences of the United States of America. 2000. Wijnholds J, et al. [Article:10840050@PubMed] |
|
|
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology. 1999. Ambudkar S V, et al. [Article:10331089@PubMed] |
|
|
Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein. Biochemistry and cell biology = Biochimie et biologie cellulaire. 1999. Loo T W, et al. [Article:10426282@PubMed] |
|
|
Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. The Journal of pharmacology and experimental therapeutics. 1999. Chu X Y, et al. [Article:9918583@PubMed] |
|
|
Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998. Mickley L A, et al. [Article:9473242@PubMed] |
|
|
Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. International journal of cancer. Journal international du cancer. 1998. Su G M, et al. [Article:9610729@PubMed] |
|
|
P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. International journal of cancer. Journal international du cancer. 1998. Gifford A J, et al. [Article:9754649@PubMed] |
|
|
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Molecular pharmacology. 1997. Schmiedlin-Ren P, et al. [Article:9145912@PubMed] |
|
|
The physiological function of drug-transporting P-glycoproteins. Seminars in cancer biology. 1997. Schinkel A H. [Article:9441946@PubMed] |
|
|
Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. International journal of cancer. Journal international du cancer. 1996. Norris M D, et al. [Article:8598312@PubMed] |
|
|
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Molecular pharmacology. 1996. Mankhetkorn S, et al. [Article:8643093@PubMed] |
|
|
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer research. 1992. Wu L, et al. [Article:1350507@PubMed] |
|
|
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America. 1992. Mechetner E B, et al. [Article:1352877@PubMed] |
|
|
P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochemical and biophysical research communications. 1989. Kioka N, et al. [Article:2568832@PubMed] |
|
|
Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer research. 1988. Bellamy W T, et al. [Article:3180056@PubMed] |
|
|
Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 1985. Riordan J R, et al. [Article:2863759@PubMed] |
|
|
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer research. 1981. Tsuruo T, et al. [Article:7214365@PubMed] |
